Lauren Bernstein, MD
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1730241597
Payments from drug & device makers
Across 559 payments — averaging $632.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$303K
- Amgen$26K
- Sanofi US Services Inc.$20K
- Tandem Diabetes Care, Inc.$3K
- Johnson & Johnson$445
- Medtronic$224
- plus $617 from 11 others
What the payments were for
- Speaking & faculty fees$272,63889%
- Travel & lodging$30,15710%
- Food & beverage$4,6372%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 456 | $302,953 |
| Amgen(2 entities) | 11 | $25,920 |
| Sanofi US Services Inc. | 3 | $20,413 |
| Tandem Diabetes Care, Inc. | 9 | $3,000 |
| Johnson & Johnson | 52 | $445 |
| Medtronic | 4 | $224 |
| Abbott | 8 | $174 |
| Insulet Corporation | 3 | $137 |
| Cequr Corporation | 3 | $85 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Nevro Corp. | 2 | $37 |
| Senseonics, Incorporated | 1 | $29 |
| Gilead | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$222,857
- TRULICITY$48,613
- t:slim X2 insulin pump$2,350
- t-slim insulin pump$650
- MINIMED 770G$102
How this compares
$353,573 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 427 | $594,859 |
| OzempicSemaglutide | 385 | $517,847 |
| JardianceEmpagliflozin | 359 | $414,972 |
| TrulicityDulaglutide | 157 | $215,245 |
| ForteoTeriparatide | 43 | $178,321 |
| FarxigaDapagliflozin Propanediol | 102 | $99,175 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 83 | $95,347 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 62 | $84,611 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $80,042 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $46,152 |
| KerendiaFinerenone | 29 | $37,606 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $37,487 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $35,863 |
| ProliaDenosumab | 20 | $34,401 |
| SynthroidLevothyroxine Sodium | 365 | $33,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $302,953 | $999,926666 claims |
| AmgenProlia | $25,920 | $34,40120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Wendy LaneAsheville$1.9M
- Richard DoddAsheville$526K
- Victor MarlarAsheville$483K
- Michael WilliamsAsheville$25K
- Stephen WeinribAsheville$11K
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.